← Browse by Condition
Medical Condition

stroke acute stroke ischemic

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3

Stroke trials address both acute treatment (revascularization within hours of onset) and long-term secondary prevention, with rehabilitation science emerging as a distinct research priority. Advances in thrombectomy techniques have dramatically improved outcomes for large vessel occlusion strokes, driving trials to push the treatment window from 6 to 24 hours in selected patients.

Current research includes tenecteplase vs alteplase for thrombolysis, thrombectomy for medium vessel occlusions, neuroprotective agents, factor XIa inhibitors for secondary prevention with lower bleeding risk, and telerehabilitation using robotics and brain-computer interfaces. Trials in wake-up stroke and unknown time-of-onset have expanded using MRI mismatch criteria.

Trial Phases
Phase 3
1
Top Sponsors
University of Calgary 1 trial
NCT06320431 Phase 3
Recruiting

ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

Enrollment
4,000 pts
Location
Australia, Canada
Sponsor
University of Calgary
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology